p-adrenergic blocker. It is a potent specific inhibitor of cardiac 5-receptors. It is cardioselective but lacks both membrane stabilizing and intrinsic sympathomimetic activity.5 These properties led us to believe that it may be a useful drug in the management of patients with angina pectoris.
We report here on a comparison of the effects of orally administered I.C.I. 66082, practolol, and placebo on patients with established angina pectoris. We compared their symptomatic response, consumption of glyceryl trinitrate, and their ability to exercise on the bicycle ergometer while taking the three drugs in varying doses in a randomized double-blind fashion.
Patients and Methods
Eleven men, with an average age of 56 years, took part in the trial. All were being seen regularly by one of us in the outpatient clinic, and all had had typical angina pectoris for more than six months which was not crescendo in nature, was precipitated by exertion, and was rapidly relieved by rest or glyceryl trinitrate. During exercise testing all patients developed typical angina; eight had S-T segment depression of 1-0 mV or more. The three patients with typical angina and no S-T depression were among those who had proved significant coronary artery disease on selective angiography.
Six patients had normal electrocardiograms at rest and three had ST-T wave changes only. Two patients had evidence of previous myocardial infarction which had been stable at least six months before the trial. Nine of the 11 patients had had selective coronary angiograms showing significant coronary artery disease.
All 11 patients were taking (-blockers as they entered the trial. Glyceryl trinitrate was the only other drug being taken by any of the patients except for two patients who had been taking clofibrate (Atromid-S 500) for several years.
TRIAL DESIGN
Each patient was seen every two weeks for 12 visits. All visits were at the same time of day for each patient and were held in the same centrally heated room. All patients had previous experience with the bicycle ergometer (Elema Schonander) in the same room.
Run-in Period.-Before the trial started the patients were tested on the ergometer while on no medication and then at two two-weekly intervals while on placebo. This was felt to be a satisfactory "run-in" period and also established a reproducible endpoint for angina in each patient.
Cardiac Department, Guy's Hospital, London SE1 9RT P. ROY, M.R.C.P., M.R.A.C.P., Research Fellow (Present address: National Heart Hospital, London W. Drug Administration.-Oral practolol, placebo, and I.C.I. 66082 were given in the following doses, each dose being for one two-week period: I.C.I. 66082, 50 mg, 100 mg, and 200 mg; practolol 100 mg, 200 mg, and 400 mg; placebo 50 mg, 100 mg, and 200 mg. All these doses were given twice a day. The drugs were administered by the pharmacist in a double-blind randomized fashion without the knowledge of the supervising physician. All tablets looked alike and at each visit remaining tablets were counted by the pharmacist. The number of glyceryl trinitrin tablets consumed was also counted and checked against the patients' recorded consumption. Between visits the patient recorded the daily number of anginal attacks during normal activities and the number of glyceryl trinitrate tablets consumed. BRITISH MEDICAL JOURNAL 26 JULY 1975 maximum average amount of work was performed when the patients were taking I.C.I. 66082 200 mg twice a day (table I) . The mean increase in total work performed while on I.C.I. 66082 was 130°, (range 10-18Oo) and on practolol the mean increase was 5°, (range 5-7%). The increases were not statistically significant. Though practolol shares with I.C.I. 66082 cardioselectivity it also possesses intrinsic sympathomimetic activity, which on theoretical grounds could be considered disadvantageous in not producing either optimal hypotensive effect in hypertensive patients or optimal relief of angina. Some clinical trials suggest that practolol is not as effective as propranolol in the relief of angina8 though others9 do not show any significant difference between the two drugs. In our patients practolol was less effective than I.C.I. 66082 in terms of reducing frequency of anginal attacks, trinitrin consumption, and pulse and blood pressure. circulation.' 0 I.C.I. 66082 would therefore be a more appropriate r-blocker to use in those at risk of developing cardiac failure.
In our patients there was no evidence of cardiac failure while on I.C.I. 66082. I.C.I. 66082 has two other theoretical advantages: it lacks membrane stabilizing activity, which in extremely high doses is thought to delay cardiac conduction, and it has been shown in animals that I.C.I. 66082 does not cross the blood brain barrier (I.C.I. introductory animal experiments) and is therefore less likely to cause the troublesome dreams reported with some other 3-blockers."1
In our highly selected group of patients, each of whom acted as his own control, I.C.I. 66082 was found to be superior to practolol and placebo in all values assessed. The number of anginal pains and amount of trinitrin consumed in patients on I.C.I. 66082 was significantly reduced (P<0 001 and P<0 03 respectively).
The improved ability to exercise on the bicycle ergometer while taking I.C.I. 66082 was not as great as perhaps expected from the reduction in trinitrin intake. It was not uncommon to find that a patient expressed a feeling of wellbeing and a reduced incidence of anginal pains during a particular two-weekly period and yet showed no dramatic change in his work performance on the bicycle ergometer.
Each patient took I. Reports of permanent damage such as ischaemia of fingers or muscle wasting near the puncture site seem rare, and a review of 16 studies which included 4566 patients found that the incidence of such severe complications was 0-3%.' Occlusion of the artery, however, has resulted from cannulation in many patients without producing subjective or objective signs of ischaemia.2 3 We undertook a prospective study to assess the incidence of arterial occlusion and ischaemic changes in patients cannulated by members of the Nuffield Department of Anaesthetics and the relative importance of some of the factors involved in the development of these complications. Method A form was completed at the time of cannulation to provide information about the patient and the cannulation procedure.
Post-cannulation observations were all made by one anaesthetist who interviewed patients on the first, third, and seventh days after removal of the cannula. In patients with arterial occlusion more frequent observations were made over a longer period. At each interview the cannulation site and the limb in which it was situated were carefully examined and symptoms referable to the area were asked for. A note was made of the presence of haematoma (bleeding into the tissues with consequent swelling) at the cannulation site, bruising of the skin, and oedema in the limb. Infection was judged to be present when pain, erythema, and oedema were present at the cannulation site.
